Log in

Relevant bibliographies by topics / Cancer – Treatment – Research / Journal articles

To see the other types of publications on this topic, follow the link: Cancer – Treatment – Research.

Journal articles on the topic 'Cancer – Treatment – Research'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer – Treatment – Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

PATEL, PRABHUDAS, HEMANGINI VORA, BHARAT B. AGGARWAL, VARSHA GANDHI, KAPIL MEHTA, and SEN PATHAK. "Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference." Anticancer Research 36, no. 9 (2016): 4971–76. http://dx.doi.org/10.21873/anticanres.11066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

deKernion, Jean B. "IL-2 Progress in Research and Treatment of Prostate Cancer." Japanese Journal of Urology 98, no. 2 (2007): 54. http://dx.doi.org/10.5980/jpnjurol.98.54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hu, Shiwen. "Clinical Research Progress of Gardenia in the Treatment of Cancer." Asia Social Science Academy 3, no. 2 (2023): 9–12. http://dx.doi.org/10.51600/isr.2023.3.2.9.

Full text

Abstract:

Gardenia jasminoides is a traditional Chinese medicine with good pharmacological effects. Modern medicine has conducted relevant research on its effective achievements and mechanisms. This study summarizes the clinical application of gardenia by scholars, aiming to provide support for better application of gardenia.

APA, Harvard, Vancouver, ISO, and other styles

4

Mensah-Osman, Edith J. "Insomnia in cancer patients." Journal of Clinical Oncology 40, no. 16_suppl (2022): e18657-e18657. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18657.

Full text

Abstract:

e18657 Background: As new treatments extend patient survival, the quality of their lives (QoL) grows in importance. QoL may differentiate alternative treatments, and QoL assessment has become a standard component of treatment evaluations. Sleep is a key component of QoL. Insomnia can worsen pain, fatigue, depression and cognitive impairments in cancer patients. Inappropriate treatments for insomnia can further worsen these and interact with chemotherapy medications. Recognizing this, in 2019 the American Society of Clinical Oncology identified Insomnia as a key patient-reported outcome perform

APA, Harvard, Vancouver, ISO, and other styles

5

Mensah-Osman, Edith J. "Insomnia in cancer patients." Journal of Clinical Oncology 40, no. 16_suppl (2022): e18657-e18657. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18657.

Full text

Abstract:

e18657 Background: As new treatments extend patient survival, the quality of their lives (QoL) grows in importance. QoL may differentiate alternative treatments, and QoL assessment has become a standard component of treatment evaluations. Sleep is a key component of QoL. Insomnia can worsen pain, fatigue, depression and cognitive impairments in cancer patients. Inappropriate treatments for insomnia can further worsen these and interact with chemotherapy medications. Recognizing this, in 2019 the American Society of Clinical Oncology identified Insomnia as a key patient-reported outcome perform

APA, Harvard, Vancouver, ISO, and other styles

6

Ghadyalpatil, Nikhil Suresh, Chopra Supriya, Patil Prachi, Dsouza Ashwin, and Saklani Avanish. "Gastrointestinal cancers in India: Treatment perspective." South Asian Journal of Cancer 05, no. 03 (2016): 126–36. http://dx.doi.org/10.4103/2278-330x.187585.

Full text

Abstract:

AbstractGI cancer is not one cancer but is a term for the group of cancers that affect the digestive system including gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), esophageal cancer (EC), and pancreatic cancer (PC). Overall, the GI cancers are responsible for more cancers and more deaths from cancer than any other organ. 5 year survival of these cancers remains low compared to western world. Unlike the rest of the world where organ based specialities hepatobiliary, pancreatic, colorectal and esophagogastric exist , these cancers are managed in India by either a

APA, Harvard, Vancouver, ISO, and other styles

7

Passardi, Alessandro, Emanuela Scarpi, and Paola Ulivi. "Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors." International Journal of Molecular Sciences 24, no. 18 (2023): 14283. http://dx.doi.org/10.3390/ijms241814283.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Muhandiramge, Jaidyn, Erica T. Warner, John R. Zalcberg, et al. "Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)." Cancers 15, no. 4 (2023): 1017. http://dx.doi.org/10.3390/cancers15041017.

Full text

Abstract:

Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic

APA, Harvard, Vancouver, ISO, and other styles

9

Alexander, Michele. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 68, no. 1 (2001): 95–99. http://dx.doi.org/10.1023/a:1017571130144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Allison, Jesikah. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 71, no. 1 (2002): 89–93. http://dx.doi.org/10.1023/a:1013335131953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Alexander, Michele. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 59, no. 1 (2000): 93–97. http://dx.doi.org/10.1023/a:1005731227818.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Alexander, Michele. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 67, no. 2 (2001): 193–97. http://dx.doi.org/10.1023/a:1010632626567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Alexander, Michele. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 65, no. 3 (2001): 269–73. http://dx.doi.org/10.1023/a:1010646127051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Alexander, Michele. "Breast cancer research and treatment." Breast Cancer Research and Treatment 59, no. 2 (2000): 193–97. http://dx.doi.org/10.1023/a:1005921132727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Alexander, Michele. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 58, no. 1 (1999): 81–85. http://dx.doi.org/10.1023/a:1006151427889.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Alexander, Michele. "Breast cancer research and treatment." Breast Cancer Research and Treatment 58, no. 2 (1999): 187–91. http://dx.doi.org/10.1023/a:1006193112868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Alexander, Michele. "Breast cancer research and treatment." Breast Cancer Research and Treatment 61, no. 2 (2000): 177–81. http://dx.doi.org/10.1023/a:1006321831022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lippman, Marc E. "Breast Cancer Research and Treatment." Breast Cancer Research and Treatment 69, no. 1 (2001): 95–99. http://dx.doi.org/10.1023/a:1012039918757.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bravery, Benjamin, Siobhan Loughnan, and Michael Murphy. "Depression treatment research in people with cancer does not reflect cancer prevalence: findings from a systematic review." Evidence Based Mental Health 23, no. 4 (2020): 155–60. http://dx.doi.org/10.1136/ebmental-2020-300145.

Full text

Abstract:

BackgroundOne in six people with cancer will develop depression at some point in their care. Untreated depression affects quality of life, cancer care satisfaction and healthcare expenditure. Treatments for this vulnerable heterogenous population should be evidence based and specific. A common sentiment is that psychiatric research does not reflect the prevalence of patients with cancer and comorbid depression and is biased towards certain cancers, but this has not been empirically shown.Study selection and analysisA systematic review of studies on psychological and pharmacological treatments

APA, Harvard, Vancouver, ISO, and other styles

20

Panzone, John, Timothy Byler, Gennady Bratslavsky, and Hanan Goldberg. "Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers." Cancers 14, no. 6 (2022): 1536. http://dx.doi.org/10.3390/cancers14061536.

Full text

Abstract:

Traditional cancer treatments have been associated with substantial morbidity for patients. Focused ultrasound offers a novel modality for the treatment of various forms of cancer which may offer effective oncological control and low morbidity. We performed a review of PubMed articles assessing the current applications of focused ultrasound in the treatment of genitourinary cancers, including prostate, kidney, bladder, penile, and testicular cancer. Current research indicates that high-intensity focused ultrasound (HIFU) focal therapy offers effective short-term oncologic control of localized

APA, Harvard, Vancouver, ISO, and other styles

21

Zhao, Henu, Bryan Tysinger, and Dana P. Goldman. "Valuing innovations in cancer treatment." Journal of Clinical Oncology 37, no. 15_suppl (2019): e18176-e18176. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18176.

Full text

Abstract:

e18176 Background: Established in 2004 by voter referendum, the California Institute for Regenerative Medicine funds stem-cell research aimed at reducing the burden of diseases, including cancer. Incidence for certain cancer has been reduced by half in the last decades. To better understand the social benefit of medical innovation, we estimate the potential value of interventions to reduce the incidence of selected cancers. Methods: We use the Future Elderly Model (FEM) to simulate scenarios calculating the national and California disease burden of breast, colorectal, lung, and prostate cancer

APA, Harvard, Vancouver, ISO, and other styles

22

Cheng, Shih-Hsuan, Hsin-Ying Clair Chiou, Jiunn-Wei Wang, and Ming-Hong Lin. "Reciprocal Regulation of Cancer-Associated Fibroblasts and Tumor Microenvironment in Gastrointestinal Cancer: Implications for Cancer Dormancy." Cancers 15, no. 9 (2023): 2513. http://dx.doi.org/10.3390/cancers15092513.

Full text

Abstract:

Gastrointestinal (GI) cancers remain a major cause of cancer-related deaths worldwide. Despite the progress made in current treatments, patients with GI cancers still have high recurrence rates after initial treatment. Cancer dormancy, which involves the entry and escape of cancer cells from dormancy, is linked to treatment resistance, metastasis, and disease relapse. Recently, the role of the tumor microenvironment (TME) in disease progression and treatment has received increasing attention. The crosstalk between cancer-associated fibroblasts (CAF)-secreted cytokines/chemokines and other TME

APA, Harvard, Vancouver, ISO, and other styles

23

Townsley, Carol A., Shari Moura, Barbara Fitzgerald, et al. "An innovative approach to post-treatment cancer care: The After Cancer Treatment Transition Clinic (ACTT)." Journal of Clinical Oncology 30, no. 15_suppl (2012): e19522-e19522. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19522.

Full text

Abstract:

e19522 Background: Improvements in early detection and cancer therapy have led to better survival rates. Integration of cancer survivorship initiatives as part of cancer care is gaining momentum. However, post cancer treatment follow up care may not be best met in acute cancer clinics. Visits to a large urban cancer centre in Canada have increased by 30% in the past 5 years. These increased volumes have lead to prolongation of patient wait times and increased stress for health care providers. This cancer centre is undergoing a transformative change that focuses on improving the patient cancer

APA, Harvard, Vancouver, ISO, and other styles

24

Ogata, Takashi, Yota Shimoda, Kazuki Kano, et al. "Screening and treatment strategy for double cancer for esophageal cancer surgery patients." Journal of Clinical Oncology 38, no. 4_suppl (2020): 336. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.336.

Full text

Abstract:

336 Background: Esophageal cancer treatment, especially esophagectomy, is highly invasive, so treatment strategies are considered in view of existing double cancers. On the other hand, in Japan, 90% of esophageal cancers are squamous cell carcinoma, and it is known that there are a large proportion of head and neck cancers for double cancers as field cancerization. Methods: The aim of this study is to investigate the types of double cancer, simultaneous/metachronous, and the frequency and treatment policy of head and neck cancer as a particularly high coexistence rate for esophageal cancer sur

APA, Harvard, Vancouver, ISO, and other styles

25

Im, Cindy, Yutaka Yasui, Emily Stene, et al. "Treatment and treatment-related toxicity following subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 10051. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10051.

Full text

Abstract:

10051 Background: Long-term survivors of childhood cancer are at high risk for treatment-related breast cancer and have elevated mortality risk after a breast cancer diagnosis than the general population. There is no standard of care for women with treatment-related breast cancer, and treatment patterns and risk for toxicity are not known. Methods: Female survivors in CCSS diagnosed and treated for childhood cancer between 1970-1999 who developed a subsequent breast cancer (N = 344) were matched with females with sporadic breast cancer (multi-institution sampling; 1:1 matching ratio) on age at

APA, Harvard, Vancouver, ISO, and other styles

26

Barinaga, M. "CANCER RESEARCH: Treatment Marks Cancer Cells for Death." Science 278, no. 5340 (1997): 1037. http://dx.doi.org/10.1126/science.278.5340.1037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Recent Results in Cancer Research: Rectal Cancer Treatment." Diseases of the Colon & Rectum 49, no. 10 (2006): 1644–45. http://dx.doi.org/10.1007/s10350-006-0630-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mastrangelo, Stefano. "Special Issue: Childhood Brain Cancer Treatment." Cancers 15, no. 21 (2023): 5278. http://dx.doi.org/10.3390/cancers15215278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Wang, Shuo, Anna Prizment, Bharat Thyagarajan, and Anne Blaes. "Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment." Cancers 13, no. 3 (2021): 427. http://dx.doi.org/10.3390/cancers13030427.

Full text

Abstract:

Rapid improvements in cancer survival led to the realization that many modalities used to treat or control cancer may cause accelerated aging in cancer survivors. Clinically, “accelerated aging” phenotypes in cancer survivors include secondary cancers, frailty, chronic organ dysfunction, and cognitive impairment, all of which can impact long-term health and quality of life in cancer survivors. The treatment-induced accelerated aging in cancer survivors could be explained by telomere attrition, cellular senescence, stem cell exhaustion, DNA damage, and epigenetic alterations. Several aging cloc

APA, Harvard, Vancouver, ISO, and other styles

30

Israel Osejie Okoduwa, Bankole Ibrahim Ashiwaju, Jane Osareme Ogugua, Jeremiah Olawumi Arowoogun, Kehinde Feranmi Awonuga, and Evangel Chinyere Anyanwu. "Reviewing the progress of cancer research in the USA." World Journal of Biology Pharmacy and Health Sciences 17, no. 2 (2024): 068–79. http://dx.doi.org/10.30574/wjbphs.2024.17.2.0046.

Full text

Abstract:

This review provides a comprehensive analysis of the progress made in cancer research within the United States. Over the past few decades, significant strides have been taken to understand the complexities of cancer, leading to breakthroughs in diagnostics, treatment modalities, and overall patient care. The review explores key themes, including advancements in genomic medicine, immunotherapy, and personalized treatment approaches. Advancements in genomic medicine have emerged as a cornerstone of cancer research, allowing for a deeper understanding of the genetic basis of various cancers. The

APA, Harvard, Vancouver, ISO, and other styles

31

Israel, Osejie Okoduwa, Ibrahim Ashiwaju Bankole, Osareme Ogugua Jane, Olawumi Arowoogun Jeremiah, Feranmi Awonuga Kehinde, and Chinyere Anyanwu Evangel. "Reviewing the progress of cancer research in the USA." World Journal of Biology Pharmacy and Health Sciences 17, no. 2 (2024): 068–79. https://doi.org/10.5281/zenodo.11254984.

Full text

Abstract:

This review provides a comprehensive analysis of the progress made in cancer research within the United States. Over the past few decades, significant strides have been taken to understand the complexities of cancer, leading to breakthroughs in diagnostics, treatment modalities, and overall patient care. The review explores key themes, including advancements in genomic medicine, immunotherapy, and personalized treatment approaches. Advancements in genomic medicine have emerged as a cornerstone of cancer research, allowing for a deeper understanding of the genetic basis of various cancers. The

APA, Harvard, Vancouver, ISO, and other styles

32

Suzuki, Kazufumi, and Hisahiro Matsubara. "Recent Advances in p53 Research and Cancer Treatment." Journal of Biomedicine and Biotechnology 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/978312.

Full text

Abstract:

TP53, encoding p53, is one of the most famous tumor suppressor genes. The majority of human cancers demonstrate the inactivation of the p53 pathway. Mutant p53 not only, no longer, functions as a tumor suppressor but can also exert tumor-promoting effects. The basic function of p53 is to respond to cellular stress. We herein review the recent advances in p53 research and focus on apoptosis, cell cycle arrest, and senescence in response to stress. We also review the clinical applications of p53-based therapy for human cancer.

APA, Harvard, Vancouver, ISO, and other styles

33

Bodmer, Walter, and Vita Golubovskaya. "Cancer Immunotherapy: Where Next?" Cancers 15, no. 8 (2023): 2358. http://dx.doi.org/10.3390/cancers15082358.

Full text

Abstract:

The fundamental problem of dealing with cancer is that cancer cells are so like normal cells that it is very hard to find differences that can be a basis for treatment without severe side effects. The key to successful cancer immunotherapy will be based on a very careful choice of cancer targets that are sufficiently cancer specific not to cause serious side effects. There are two fundamentally different ways to deploy the immune system for such cancer treatments. One is to increase the efficacy of the cancer patient’s own immune system so that it attacks these differences. This has been achie

APA, Harvard, Vancouver, ISO, and other styles

34

Bouchardy, Christine, Elisabetta Rapiti, Stina Blagojevic, Anne-Thérèse Vlastos, and Georges Vlastos. "Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment." Journal of Clinical Oncology 25, no. 14 (2007): 1858–69. http://dx.doi.org/10.1200/jco.2006.10.4208.

Full text

Abstract:

Despite increased interest in treatment of senior cancer patients, older patients are much too often undertreated. This review aims to present data on treatment practices of older women with breast and gynecologic cancers and on the consequences of undertreatment on patient outcome. We also discuss the reasons and validity of suboptimal care in older patients. Numerous studies have reported suboptimal treatment in older breast and gynecologic cancer patients. Undertreatment displays multiple aspects: from lowered doses of adjuvant chemotherapy to total therapeutic abstention. Undertreatment al

APA, Harvard, Vancouver, ISO, and other styles

35

Erichsen, H. C., and S. J. Chanock. "SNPs in cancer research and treatment." British Journal of Cancer 90, no. 4 (2004): 747–51. http://dx.doi.org/10.1038/sj.bjc.6601574.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Drennan, Vari. "Prostate cancer screening and treatment research." Primary Health Care 20, no. 10 (2010): 13. http://dx.doi.org/10.7748/phc.20.10.13.s23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Musgrave, Elaine. "Tailoring Treatment in Translational Cancer Research." Clinical and Translational Science 2, no. 3 (2009): 178–79. http://dx.doi.org/10.1111/j.1752-8062.2008.00115.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Pawelec, Graham, and Valquiria Bueno. "Ageing and Cancer Research & Treatment." Ageing and Cancer Research & Treatment 1, no. 1 (2023): 0. http://dx.doi.org/10.37155/2972-4759-2023-01-01-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Olson, David C., Khaled Mohamed Abou El-Ezz, and Peter T. Silberstein. "Choice of therapy and time to first treatment for patients with colon cancer: A National Cancer Database analysis." Journal of Clinical Oncology 31, no. 15_suppl (2013): e14642-e14642. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14642.

Full text

Abstract:

e14642 Background: Insurance status has been shown to affect adherence to guidelines in the treatment of colon cancer1. This study aims to investigate trends in management of colon cancer and time to first treatment in patients with various insurance types using the National Cancer Database (NCDB). Methods: Treatment data for 845,121 patients and time to first treatment data for 497,993 patients diagnosed with colon cancer between 2000 and 2010 were identified using the NCDB. Reported utilization of treatment and time to first treatment were analyzed by insurance status. Results: Among all sta

APA, Harvard, Vancouver, ISO, and other styles

40

Jiang, Yixiao. "Research Progress of Polysaccharides and Cancer Treatment." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 1499–504. http://dx.doi.org/10.54097/hset.v36i.6275.

Full text

Abstract:

Over the past decade, scientists have already discovered several methods for cancer treatment, however, most of the treatments have various kinds of negative side effects. Researchers have focused on creating medications with few adverse effects for cancer because it is one of the most fatal diseases. Due to their anti-tumor properties and non-toxic attributes, bioactive macromolecules like polysaccharides are seen as viable options against cancer. Nowadays, there have been many studies on the mechanisms and possibilities of polysaccharides against tumors, and this paper attempts to summarize

APA, Harvard, Vancouver, ISO, and other styles

41

Chen, Guo-Qing, Yi Nan, Shi-Cong Huang, et al. "Research progress of ginger in the treatment of gastrointestinal tumors." World Journal of Gastrointestinal Oncology 15, no. 11 (2023): 1835–51. http://dx.doi.org/10.4251/wjgo.v15.i11.1835.

Full text

Abstract:

Cancer seriously endangers human health. Gastrointestinal cancer is the most common and major malignant tumor, and its morbidity and mortality are gradually increasing. Although there are effective treatments such as radiotherapy and chemotherapy for gastrointestinal tumors, they are often accompanied by serious side effects. According to the traditional Chinese medicine and food homology theory, many materials are both food and medicine. Moreover, food is just as capable of preventing and treating diseases as medicine. Medicine and food homologous herbs not only have excellent pharmacological

APA, Harvard, Vancouver, ISO, and other styles

42

Ma, Yu-Shui, Wen Li, Yu Liu, Yi Shi, Qin-Lu Lin, and Da Fu. "Targeting Colorectal Cancer Stem Cells as an Effective Treatment for Colorectal Cancer." Technology in Cancer Research & Treatment 19 (January 1, 2020): 153303381989226. http://dx.doi.org/10.1177/1533033819892261.

Full text

Abstract:

As one of the common cancers that threaten human life, the recurrence and metastasis of colorectal cancer seriously affect the prognosis of patients. Although new drugs and comprehensive treatments have been adopted, the current treatment effect on this tumor, especially in advanced colorectal cancer, is still not satisfactory. More and more evidence shows that tumors are likely to be a stem cell disease. In recent years, the rise of cancer stem cell theory has provided a new way for cancer treatment. Studies have found that a small number of special cells in colorectal cancer tissues that ind

APA, Harvard, Vancouver, ISO, and other styles

43

Ullman, K. "Navigating Cancer Treatment." JNCI Journal of the National Cancer Institute 106, no. 2 (2014): dju031. http://dx.doi.org/10.1093/jnci/dju031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Nguyen, Khoa, Emily McConnell, Orielle Edwards, Bridgette M. Collins-Burow, and Matthew E. Burow. "GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies." Cancer Drug Resistance 5, no. 3 (2022): 721–6. http://dx.doi.org/10.20517/cdr.2022.30.

Full text

Abstract:

Research has led to the development of tailored treatment options for different cancers in different patients. Despite some treatments being able to provide remarkable responses, nearly all current treatments encounter the same issue: resistance. Here, we discuss our experiences with how breast cancers resist therapies. The focus of our discussion revolves around the cancer stem cell subpopulation and their mechanisms for resistance.

APA, Harvard, Vancouver, ISO, and other styles

45

Kawiak, Anna. "Molecular Research and Treatment of Breast Cancer." International Journal of Molecular Sciences 23, no. 17 (2022): 9617. http://dx.doi.org/10.3390/ijms23179617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ganz, Patricia A., and Erin E. Hahn. "Implementing a Survivorship Care Plan for Patients With Breast Cancer." Journal of Clinical Oncology 26, no. 5 (2008): 759–67. http://dx.doi.org/10.1200/jco.2007.14.2851.

Full text

Abstract:

Breast cancer survivors account for 23% of the more than 10 million cancer survivors in the United States today. The treatments for breast cancer are complex and extend over a long period of time. The post-treatment period is characterized by gradual recovery from many adverse effects from treatment; however, many symptoms and problems persist as late effects (eg, infertility, menopausal symptoms, fatigue), and there may be less frequent long-term effects (eg, second cancers, lymphedema, osteoporosis). There is increasing recognition of the need to summarize the patient's course of treatment i

APA, Harvard, Vancouver, ISO, and other styles

47

Vergote, Ignace, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, and David Scott Miller. "Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment." Cancers 15, no. 3 (2023): 636. http://dx.doi.org/10.3390/cancers15030636.

Full text

Abstract:

Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities and potential drug–drug interactions. As such, there is a high unmet need to develop additional therapies to enhance the efficacy of SOC treatments without increasing toxicity. Tumor Treating Fields (T

APA, Harvard, Vancouver, ISO, and other styles

48

Marty, Denise. "Boris Pasche (ed): Cancer Genetics: Cancer Treatment and Research." Journal of Genetic Counseling 21, no. 2 (2011): 353–54. http://dx.doi.org/10.1007/s10897-011-9423-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Vijayalaxmi, Charles R. Thomas, Russel J. Reiter, and Terence S. Herman. "Melatonin: From Basic Research to Cancer Treatment Clinics." Journal of Clinical Oncology 20, no. 10 (2002): 2575–601. http://dx.doi.org/10.1200/jco.2002.11.004.

Full text

Abstract:

ABSTRACT: Melatonin, the chief secretory product of the pineal gland, is a direct free radical scavenger, an indirect antioxidant, as well as an important immunomodulatory agent. In both in vitro and in vivo investigations, melatonin protected healthy cells from radiation-induced and chemotherapeutic drug–induced toxicity. Furthermore, several clinical studies have demonstrated the potential of melatonin, either alone or in combination with traditional therapy, to yield a favorable efficacy to toxicity ratio in the treatment of human cancers. This study reviews the literature from laboratory i

APA, Harvard, Vancouver, ISO, and other styles

50

Streck, Brennan, Jacqueline B. Vo, Carolyn Brandt, et al. "Understanding cancer treatment decision making among cancer survivors." Journal of Clinical Oncology 41, no. 16_suppl (2023): e24076-e24076. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e24076.

Full text

Abstract:

e24076 Background: Nearly 20% of U.S. cancer survivors develop late cardiovascular disease (CVD) as a result of cardiotoxic cancer treatments. Patients and providers may consider alternative treatment options to lower cardiotoxicity risk, which may present a trade-off between reducing relatively near-term relapse/recurrence vs. preventing long-term CVD. Patients’ decision-making processes (e.g., delay discounting, risk perceptions for CVD vs. cancer) may affect such choices. However, these decision-making factors are not well understood in this context; nor is their association with treatment

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!